231 related articles for article (PubMed ID: 21924623)
1. Biosimilars--global issues, national solutions.
Knezevic I; Griffiths E
Biologicals; 2011 Sep; 39(5):252-5. PubMed ID: 21924623
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of similar biotherapeutic products (SBPs): scientific principles and their implementation.
Knezevic I
Biologicals; 2011 Sep; 39(5):256-61. PubMed ID: 21907589
[TBL] [Abstract][Full Text] [Related]
3. Regulatory guidelines for biosimilars in Malaysia.
Abas A
Biologicals; 2011 Sep; 39(5):339-42. PubMed ID: 21784655
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation.
Malhotra H
Biologicals; 2011 Sep; 39(5):321-4. PubMed ID: 21784652
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars: opportunity or cause for concern?
Roger SD; Mikhail A
J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
[TBL] [Abstract][Full Text] [Related]
6. Concept of biosimilar products in Jordan.
Haddadin RD
Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
[TBL] [Abstract][Full Text] [Related]
7. The regulatory framework for similar biotherapeutic products in Cuba.
Hechavarría Núñez Y; Pérez Massipe RO; Orta Hernández SD; Muñoz LM; Jacobo Casanueva OL; Pérez Rodríguez V; Domínguez Morales RB; Pérez Cristiá RB
Biologicals; 2011 Sep; 39(5):317-20. PubMed ID: 21930393
[TBL] [Abstract][Full Text] [Related]
8. Current development in regulation of similar biotherapeutic products in Brazil.
Castanheira LG; Barbano DB; Rech N
Biologicals; 2011 Sep; 39(5):308-11. PubMed ID: 21868247
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of similar biotherapeutic products: scientific and regulatory challenges.
Griffiths E; Thorpe R; Wadhwa M; Sohn Y
Biologicals; 2011 Sep; 39(5):249. PubMed ID: 21925898
[No Abstract] [Full Text] [Related]
10. Biosimilars: current status and future directions.
Roger SD
Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
[TBL] [Abstract][Full Text] [Related]
11. Summary of the diverse situation of similar biotherapeutic products in the selected countries (August 2010).
Kang HN
Biologicals; 2011 Sep; 39(5):304-7. PubMed ID: 21880507
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars: recent developments.
Covic A; Kuhlmann MK
Int Urol Nephrol; 2007; 39(1):261-6. PubMed ID: 17333516
[TBL] [Abstract][Full Text] [Related]
13. A biosimilar industry view on the implementation of the WHO guidelines on evaluating similar biotherapeutic products.
Schiestl M
Biologicals; 2011 Sep; 39(5):297-9. PubMed ID: 21784654
[TBL] [Abstract][Full Text] [Related]
14. Current regulatory and scientific considerations for approving biosimilars in Iran.
Hadavand N; Valadkhani M; Zarbakhsh A
Biologicals; 2011 Sep; 39(5):325-7. PubMed ID: 21873077
[TBL] [Abstract][Full Text] [Related]
15. China's perspective on similar biotherapeutic products.
Liang C; Wang J
Biologicals; 2011 Sep; 39(5):312-6. PubMed ID: 21924622
[TBL] [Abstract][Full Text] [Related]
16. Clinical programs in the development of similar biotherapeutic products: rationale and general principles.
Berghout A
Biologicals; 2011 Sep; 39(5):293-6. PubMed ID: 21911300
[TBL] [Abstract][Full Text] [Related]
17. Towards regulation of similar biotherapeutic products: Thailand's perspective.
Thanaphollert P; Tungsanga K
Biologicals; 2011 Sep; 39(5):346-7. PubMed ID: 21917474
[TBL] [Abstract][Full Text] [Related]
18. The use of bioassays for the characterisation and control of biological therapeutic products produced by biotechnology.
Thorpe R; Wadhwa M; Mire-Sluis A
Dev Biol Stand; 1997; 91():79-88. PubMed ID: 9413686
[TBL] [Abstract][Full Text] [Related]
19. Basic facts about biosimilars.
Nowicki M
Kidney Blood Press Res; 2007; 30(5):267-72. PubMed ID: 17622764
[TBL] [Abstract][Full Text] [Related]
20. Regulatory pathways for vaccines for developing countries.
Milstien J; Belgharbi L
Bull World Health Organ; 2004 Feb; 82(2):128-33. PubMed ID: 15042235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
